Semaglutide Works for Weight Loss Across All Racial and Ethnic Groups
Semaglutide 2.4 mg produced significant and consistent weight loss across racial and ethnic subgroups in the STEP trials, with comparable safety.
Quick Facts
What This Study Found
Semaglutide 2.4 mg produced significant and consistent weight loss across racial and ethnic subgroups in the STEP trials, with comparable safety profiles.
Key Numbers
STEP 1 and 3 data were pooled; STEP 2 analyzed separately. Primary outcome: percent body weight change from baseline. Semaglutide 2.4 mg given once weekly subcutaneously.
How They Did This
Post hoc subgroup analysis of three phase 3 randomized controlled trials (STEP 1, 2, and 3) by race and ethnicity.
Why This Research Matters
Obesity disproportionately affects certain racial and ethnic groups. Confirming that semaglutide works across these populations helps ensure equitable treatment access and expectations.
The Bigger Picture
Obesity disproportionately affects Black, Hispanic, and Native American communities. Confirming that semaglutide works across these populations is essential for equitable treatment access.
What This Study Doesn't Tell Us
Post hoc subgroup analysis has less statistical power than a study designed for this comparison. Some subgroups may have been small.
Questions This Raises
- ?Are there clinically meaningful differences in weight loss magnitude between groups?
- ?Do cultural and socioeconomic factors affect real-world outcomes differently?
Trust & Context
- Key Stat:
- Consistent across all groups Semaglutide 2.4 mg produced significant weight loss regardless of racial or ethnic background in the STEP trials
- Evidence Grade:
- Rated strong: post hoc analysis of three large phase 3 randomized controlled trials with explicit subgroup analysis.
- Study Age:
- Published in 2024. Addresses an important health equity question as GLP-1 drug access expands.
- Original Title:
- Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials.
- Published In:
- Obesity (Silver Spring, Md.), 32(7), 1268-1280 (2024)
- Authors:
- Rubino, Domenica(4), Angelene, Hanna, Fabricatore, Anthony(3), Ard, Jamy
- Database ID:
- RPEP-09178
Evidence Hierarchy
Frequently Asked Questions
Does semaglutide work the same for all races?
The STEP trials showed consistent weight loss across racial and ethnic subgroups, with similar safety profiles.
Why is racial diversity in drug trials important?
Genetic and metabolic differences can affect drug response. Confirming efficacy across diverse populations ensures everyone can benefit equally.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09178APA
Rubino, Domenica; Angelene, Hanna; Fabricatore, Anthony; Ard, Jamy. (2024). Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials.. Obesity (Silver Spring, Md.), 32(7), 1268-1280. https://doi.org/10.1002/oby.24042
MLA
Rubino, Domenica, et al. "Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials.." Obesity (Silver Spring, 2024. https://doi.org/10.1002/oby.24042
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and safety of semaglutide 2.4 mg by race and ethnic..." RPEP-09178. Retrieved from https://rethinkpeptides.com/research/rubino-2024-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.